Tags

Type your tag names separated by a space and hit enter

[Comparison of quality of life in multiple system atrophy and Parkinson's disease].
Rev Neurol (Paris). 2009 Nov; 165(11):911-5.RN

Abstract

PURPOSE

Quality of life (QoL) in multiple system atrophy (MSA) is thought to be poorer than in Parkinson's disease (PD), primarily because of motor impairment, autonomic dysfunction and depression. The aim of the study was to investigate QoL in 10 patients with probable MSA (parkinsonian subtype) compared with 10 PD patients matched for motor disability on UPDRS III motor score.

METHODS

All patients were ambulatory and non-demented. Mean durations of disease in MSA and PD patients were respectively 3.6 and 9.0 years. QoL was assessed using the SF-36 health-related questionnaire and a life satisfaction visual analogue scale. Patients were also evaluated for cognitive function (Mattis Dementia Rating Scale [Mattis DRS], Wisconsin Card Sorting Test [WCST], Stroop, Fluencies), depression (Beck Depression Inventory-II [BDI-II]), apathy (Modified Apathy Evaluation Scale) and were screened for non-motor symptoms (NMS Quest).

RESULTS

The only difference in QoL between MSA and PD patients matched for motor disability was that the SF-36 vitality subscore was more impaired in MSA and negatively correlated with interference index on Stroop word colour testing. Depression and non-motor symptoms were associated with poorer QoL in both groups. Among MSA patients, cognitive impairment (Stroop interference index) and apathy also had a negative impact.

CONCLUSION

There was no major difference in QoL between MSA and PD patients matched for motor disability with a disease duration about 5 years longer. The SF-36 vitality subscore was more impaired in MSA and associated with interference sensitivity.

Links

Publisher Full Text
linkinghub.elsevier.com
em-consulte.com

Authors+Show Affiliations

Torny F
CMRR Limousin, 15, rue du Docteur-Raymond-Marcland, 87025 Limoges cedex, France. frederic.torny@chu-limoges.fr
Lacoste M
No affiliation info available
Videaud H
No affiliation info available
Chouly M
No affiliation info available
Parveau MC
No affiliation info available
Couratier P
No affiliation info available

MeSH

Activities of Daily LivingAge of OnsetAgedAntidepressive AgentsColor VisionEmotionsFemaleHumansMaleMiddle AgedMultiple System AtrophyParkinson DiseaseQuality of LifeStroop Test

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

fre

PubMed ID

19324385

Citation

Torny, F, et al. "[Comparison of Quality of Life in Multiple System Atrophy and Parkinson's Disease]." Revue Neurologique, vol. 165, no. 11, 2009, pp. 911-5.
Torny F, Lacoste M, Videaud H, et al. [Comparison of quality of life in multiple system atrophy and Parkinson's disease]. Rev Neurol (Paris). 2009;165(11):911-5.
Torny, F., Lacoste, M., Videaud, H., Chouly, M., Parveau, M. C., & Couratier, P. (2009). [Comparison of quality of life in multiple system atrophy and Parkinson's disease]. Revue Neurologique, 165(11), 911-5. https://doi.org/10.1016/j.neurol.2009.02.001
Torny F, et al. [Comparison of Quality of Life in Multiple System Atrophy and Parkinson's Disease]. Rev Neurol (Paris). 2009;165(11):911-5. PubMed PMID: 19324385.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Comparison of quality of life in multiple system atrophy and Parkinson's disease]. AU - Torny,F, AU - Lacoste,M, AU - Videaud,H, AU - Chouly,M, AU - Parveau,M-C, AU - Couratier,P, Y1 - 2009/03/25/ PY - 2008/10/21/received PY - 2008/12/05/revised PY - 2009/02/15/accepted PY - 2009/3/28/entrez PY - 2009/3/28/pubmed PY - 2010/3/25/medline SP - 911 EP - 5 JF - Revue neurologique JO - Rev Neurol (Paris) VL - 165 IS - 11 N2 - PURPOSE: Quality of life (QoL) in multiple system atrophy (MSA) is thought to be poorer than in Parkinson's disease (PD), primarily because of motor impairment, autonomic dysfunction and depression. The aim of the study was to investigate QoL in 10 patients with probable MSA (parkinsonian subtype) compared with 10 PD patients matched for motor disability on UPDRS III motor score. METHODS: All patients were ambulatory and non-demented. Mean durations of disease in MSA and PD patients were respectively 3.6 and 9.0 years. QoL was assessed using the SF-36 health-related questionnaire and a life satisfaction visual analogue scale. Patients were also evaluated for cognitive function (Mattis Dementia Rating Scale [Mattis DRS], Wisconsin Card Sorting Test [WCST], Stroop, Fluencies), depression (Beck Depression Inventory-II [BDI-II]), apathy (Modified Apathy Evaluation Scale) and were screened for non-motor symptoms (NMS Quest). RESULTS: The only difference in QoL between MSA and PD patients matched for motor disability was that the SF-36 vitality subscore was more impaired in MSA and negatively correlated with interference index on Stroop word colour testing. Depression and non-motor symptoms were associated with poorer QoL in both groups. Among MSA patients, cognitive impairment (Stroop interference index) and apathy also had a negative impact. CONCLUSION: There was no major difference in QoL between MSA and PD patients matched for motor disability with a disease duration about 5 years longer. The SF-36 vitality subscore was more impaired in MSA and associated with interference sensitivity. SN - 0035-3787 UR - https://www.unboundmedicine.com/medline/citation/19324385/[Comparison_of_quality_of_life_in_multiple_system_atrophy_and_Parkinson's_disease]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0035-3787(09)00144-1 DB - PRIME DP - Unbound Medicine ER -